Genetic polymorphism in exon 4 of cytochrome P450 CYP2C9 may be associated with warfarin sensitivity in Chinese patients

Blood

Volumn 98, Issue 8, 2001, Pages 2584-2587

  Leung, Anskar Y H ^a   Chow, Howard C H ^a   Kwong, Y L ^a   Lie, Albert K W ^a   Fung, Alvin T K ^a   Chow, W H ^a   Yip, Alex S B ^a   Liang, Raymond ^a,b  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b QUEEN MARY HOSPITAL   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; CYSTEINE; CYTOCHROME P450; CYTOCHROME P450 2C9; LEUCINE; VALINE; WARFARIN;

ADULT; AGED; ANTICOAGULATION; ARTICLE; CAUCASIAN; CHINESE; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG SENSITIVITY; ENZYME ANALYSIS; EXON; GENE AMPLIFICATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOSITY; HUMAN; INDIVIDUALITY; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RACE DIFFERENCE;

EID: 0035889154     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V98.8.2584     Document Type: Article

References (19)

1. Poller L, Taberner DA. Dosage and control of oral anticoagulants: an international collaborative survey. Br J Haematol. 1982;51:479-485.
2. Fihn SD, Callahan CM, Martin DC, et al. The risk for and severity of bleeding complications in elderly patients treated with wartafin: the National Consortium of Anticoagulation Clinics. Ann Intern Med. 1996; 124:970-979.
3. James AH, Britt RP, Raskino CL, Thompson SG. Factors affecting the maintenance dose of warfarin. J Clin Pathol.1992;45:704-706.
4. Hallak HO, Wedlund PJ, Modi MW, et al. High clearance of (s)-warfarin in a warfarin-resistant subject. Br J Clin Pharmacol. 1993;35:327-330.
5. Kaminsky LS, Zhang ZY. Human P450 metabolism of warfarin. Pharmacol Ther. 1997;73:67-74.
6. Stubbins MJ, Harries LW, Smith G, et al. Genetic analysis of the human cytochrome P450 CYP2C9 locus. Pharmacogenetics. 1996;6:429-439.
7. Veronese ME, Doecke CJ, Mackenzie PI, et al. Site-directed mutagenesis of human liver cytochrome P-450 isoenzymes in the CYP2C family. Biochem J. 1993;289:533-538.
8. Steward DJ, Haining RJ, Henne KR. Genetic association between sensitivity to warfarin and expression of CYP2C9*3. Pharmacogenetics. 1997; 7:361-367.
9. Aithal GP, Day CP, Kesteven PJL, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet. 1999;353:717-719.
10. Taube J, Halsalt D, Baglin T. Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood.2000;96:1816-1819.
11. Leung AYH, Liang RHS. Studies on cytochrome P450 CYP2C9 genetic polymorphism in Chinese patients receiving warfarin [abstract]. Blood. 1999;94(suppl 1):3646.
12. Wang SL, Huang JD, Lai MD, Tsai JJ, Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese. Pharmacogenetics. 1995;5:37-42.
13. Yu HCM, Chan TYK, Critchley JAJH, Woo KS. Factors determining the maintenance dose of warfarin in Chinese patients. Q J Med. 1996;89:127-135.
14. Crespi CL, Miller VP. The R144C change in the CYP2C9*2 alleles alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase. Pharmacogenetics. 1997;7:203-210.
15. Ridderstr̈m M, Masimirembwa C, Trump-Kallmeyer S, et al. Arginines 97 and 108 in CYP2C9 are important determinants of the catalyric function. Biochem Biophys Res Commun. 2000;270:983-987.
16. Afzelius L, Zamora I, Ridderström M, et al. Competitive CYP2C9 inhibitors: enzyme inhibition studies, protein homology modeling, and three-dimensional quantitative structure-activity relationship analysis. Mol Pharmacol 2001;59:909-919.
17. Payne VA, Chang YT, Loew GH. Homology modeling and substrate binding study of human CYP2C9 enzyme. Protein. 1999;37:176-190.
18. Margaglione M, Colaizzo D, D'Andrea G, et al. Genetic modulation of oral anticoagulation with warfarin. Thromb Haemost. 2000;84:775-778.
19. Caraco Y. Genetic determinants of drug responsiveness and drug interactions. Ther Drug Monit. 1998;20:517-524.